融合抑制剂的研究进展

Progress of Study on Fusion Inhibitors

下载PDF

导出

摘要艾滋病是由人免疫缺陷病毒引起的 ,HIV包膜糖蛋白与CD4结合是HIV融合过程的第一步 ,阻断HIV的融合过程即可阻止HIV的复制和传播。因此近年来各类融合抑制剂的研究获得了较大进展。 AIDS is caused by human immunodeficiency virus (HIV). Binding of the HIV ENV to CD4 is the initial step in the fusion cascade, so inhibiting HIV fusion cascade will inhibit the replication and spread of HIV. In this article, the present status and progress of several kinds of fusion inhibitors were reviewed. [

作者刘永久赵桂森徐玉文

机构地区山东侨联医院药剂科山东大学药学院山东省药品检验所

出处《药学进展》 CAS 2004年第4期168-172,共5页 Progress in Pharmaceutical Sciences

基金山东省自然科学基金资助项目 (Y2 0 0 3C19)

关键词融合抑制剂研究进展人免疫缺陷病毒艾滋病 HIV包膜糖蛋白 AIDS,HIV,Fusion,Inhibitor

分类号 R9787 [医药卫生—药品]

引文网络
相关文献

参考文献25

1Fauci A S. The human immunodeficiency virus infectivity and mechechanisms of pathogenesis[J]. Science, 1988,239(4840):617-622.
2Matsushita S. Current status and future issues in the treatment of HIV-1 infection[J]. Int J Hematol, 2000, 72 (1):20-27.
3Kwong P D, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody (see comments)[J]. Nature, 1998,393 (6686):648-659.
4Willett B J, Adema K, Heveker N, et al. The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus[J]. J Virol, 1998, 72 (8):6475-6481.
5Celia C. LaBranche, George Galasso, John P. Moore, et al. HIV fusion and its inhibition[J]. Antiviral Research. 2001,50: 95-115.
6Geijtenbeek T B, Kwon D S, Torensma R, et al. DC-SIGN, a dendritic cellspecific HIV-1-binding protein that enhances trans-infection of T cells (see comments)[J]. Cell, 2000,100 (5): 587-597.
7Mondor I, Ugolini S, Sattentau QJ. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans[J]. J Virol, 1998, 72(5):3623-3634.
8Rizzuto C, Sodroski J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120[J]. AIDS Res Hum Retroviruses, 2000, 16(8):741-749.
9Rizzuto C D, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding(see comments)[J]. Science,1998, 280(5371):1949-1953.
10Chan D C, Kim P S. HIV entry and its inhibition[J]. Cell, 1998, 93(5):681-684.

1融合抑制剂治疗HIV感染的新一类药[J].德国临床用药,2000,3(3):21-22.
2赵云利,宋礼华.抗病毒药物治疗艾滋病研究的探讨[J].河南中医学院学报,2006,21(2):8-10. 被引量：2
3宁慧娟.新一代融合抑制剂对出现T-20耐受的患者有效[J].传染病网络动态,2003(11):8-9.
4罗燕.艾滋病抗病毒治疗现状[J].临床医药文献电子杂志,2015,2(34):7149-7149.
5FDA加速FUZEON批准进程[J].中国处方药,2003(4):79-79.
6许燕珍,吴文言.以gp41为靶点的HIV-1肽类融合抑制剂研究进展[J].临床医学,2016,36(3):117-120.
7周艳秋,朱小珍,高玉珍,高洁.上海市某区2008年艾滋病病毒(HIV)抗体检测情况分析[J].上海医药,2010,31(A01):60-61. 被引量：2
8康来仪,崔海清.AZT可阻断HIV母婴传播[J].适宜诊疗技术,1999,17(1):31-31.
9融合抑制剂PRO140可降低小鼠模型中HIV的含量[J].传染病网络动态,2001(6):25-26.
10刘莉莉,吕焕菊,奚梅,王成库,李子民.抗艾滋病药物的研究概况[J].沈阳药科大学学报,2009,26(B07):122-122.

药学进展

2004年第4期

浏览历史

内容加载中请稍等...

融合抑制剂的研究进展

参考文献25

相关作者

相关机构

相关主题

浏览历史